Northwire Canada EditionSunday, July 12, 2026
Sign inSubscribe
Northwire
⌕
GLDN 0.055 +0.0% BRON 0.040 +0.0% BTO 5.43 −0.7% ESK 0.365 −2.7% AUMN 0.275 +0.0% GGX 0.040 +0.0% S 0.155 +29.2% NNX 0.035 +0.0% ABX 51.90 −0.6% TTS 2.40 −4.0% FCI 0.400 −9.1% GR 0.075 +0.0% AII 23.38 +12.4% TUNG 1.72 +1.8% LGO 1.01 −2.9% EMM 0.080 +0.0% GLDN 0.055 +0.0% BRON 0.040 +0.0% BTO 5.43 −0.7% ESK 0.365 −2.7% AUMN 0.275 +0.0% GGX 0.040 +0.0% S 0.155 +29.2% NNX 0.035 +0.0% ABX 51.90 −0.6% TTS 2.40 −4.0% FCI 0.400 −9.1% GR 0.075 +0.0% AII 23.38 +12.4% TUNG 1.72 +1.8% LGO 1.01 −2.9% EMM 0.080 +0.0%
Earnings

Aurora Spine Corporation Announces Record Third Quarter Financial Results

By The Northwire Desk — AI Analysis Nov 18, 2025 · 07:15 ASG · 0.3 Aurora Spine Corporation
ASG · Price

Executive Summary

  • Aurora Spine reported Q3 2025 revenue of $4.43 M, a 7.1% decline year‑over‑year, but achieved its fifth consecutive quarter with sales above $4.4 M.
  • EBITDAC turned positive at $165,600 for the quarter (second consecutive positive quarter), while net loss was $(0.142) M.
  • The company launched two new product platforms—DEXA‑L™ Anterior Lumbar Interbody Fusion Device and Hydra ARO Lumbar Fusion System—generating initial sales and positioning them as growth catalysts.

Key Details

  • Revenue: $4,430,755 (−7.1% YoY).
  • Gross Margin: 60.9% vs. 60.5% in Q3 2024; improvement driven by higher direct sales and lower distributor commissions.
  • Operating Expenses: $2,814,754 (flat YoY); includes $0.267 M non‑cash expenses.
  • EBITDAC: $165,600 vs. $380,117 in Q3 2024; positive for the second straight quarter.
  • Net Loss: $(141,980) vs. a profit of $71,120 in Q3 2024.
  • Basic & Diluted Loss per Share: $(0.00); unchanged from prior year.

Balance Sheet Highlights (as of Sep 30 2025)
Cash: $665,757 (down from $825,621 on Dec 31 2024).
 Receivables: $4,208,468.
Inventory: $3,818,985.
 Total Assets: $11,687,135.
* Current Liabilities: $4,575,707; Non‑current Liabilities: $3,280,520.

Product Launches
DEXA‑L™ Anterior Lumbar Interbody Fusion Device – introduced Q3 2025, achieved initial sales.
 Hydra ARO Lumbar Fusion System™ – facet fusion device launched Q3 2025, also generated early sales.

Management Commentary
CEO Trent Northcutt highlighted the launches as “growth catalysts” and emphasized focus on commercializing proprietary platforms and expanding the sales team.
 CFO Chad Clouse noted efficient operations, strong cash collections, expense discipline, and sufficient capital to pursue growth opportunities.

Conference Call
Date/Time: Tue Nov 18 2025, 11:00 a.m. ET / 8:00 a.m. PT.
 Dial‑in numbers and webcast link provided; replay available until Nov 25 2025 (teleconference) and for 90 days (webcast).

Notable Quotes

“These two launches round out the company’s mission of pivoting to developing and selling proprietary products…initial feedback has been extremely positive and should act as excellent growth catalysts.” – Trent Northcutt, CEO

“The company is operating extremely efficiently…we believe that the company is sufficiently capitalized to pursue growth opportunities.” – Chad Clouse, CFO

Read the original news release →

More from Aurora Spine Corporation

May 28, 2026 · 07:15

Aurora Spine Stabilizes Operations with First EBITDAC Profit, Yet Revenue Stagnation and Cash Burn Raise Liquidity Concerns

Earnings May 07, 2026 · 07:15

Patent Milestone Masks Cash Strain and Debt Overhang Despite EBITDAC Turnaround

Other Apr 30, 2026 · 07:15

Aurora Spine Posts Record Revenue as Turnaround Strategy Takes Hold

Earnings Mar 04, 2026 · 18:28

Aurora Spine cuts loan rate, extends insider note

Financings Mar 04, 2026 · 17:01

AURORA SPINE CORPORATION ANNOUNCES AMENDMENT TO LOAN FROM INSIDER

Financings Jan 08, 2026 · 16:28

Aurora Spine receives two U.S. patents

M&A / Property